期刊文献+

参慈胶囊联合顺铂通过PI3K/AKT/mTOR信号通路逆转人肺腺癌顺铂耐药的机制研究 被引量:22

Mechanism of Shenci capsule combined with cisplatin in reversing DDP resistance of human lung adenocarcinoma via PI3K/AKT/mTOR signaling pathway
在线阅读 下载PDF
导出
摘要 目的:探讨参慈胶囊联合顺铂是否通过PI3K/AKT/mTOR信号通路逆转接种人肺腺癌A549/DDP细胞的裸鼠体内的顺铂耐药。方法:建立裸鼠人肺腺癌移植瘤模型,随机分为对照组、参慈胶囊组、顺铂组和参慈胶囊+顺铂组。对照组予生理盐水,其余各组荷瘤裸鼠均用药21 d,断颈处死,取肿瘤组织,采用流式细胞术检测细胞周期与细胞凋亡;采用FQ-PCR技术检测A549/DDP肺癌组织PTEN、P-糖蛋白、PI3K、AKT和mTOR的mRNA表达情况。结果:参慈胶囊组、顺铂组和参慈胶囊+顺铂组与对照组比较,对人肺腺癌A549/DDP细胞的增殖均有抑制作用,其中参慈胶囊+顺铂组较其它治疗组能够进一步将人肺腺癌A549/DDP细胞阻滞于G_2/M期,促进细胞凋亡,增加PTEN的表达,抑制P-糖蛋白、PI3K、AKT和mTOR的表达。结论:参慈胶囊可能通过阻断PI3K/AKT/mTOR信号通路,促进PTEN的表达,或者抑制P-糖蛋白介导的耐药途径,增强裸鼠体内人肺腺癌A549/DDP耐药细胞对顺铂的敏感性。 AIM:To investigate the effect of Shenci capsule combined with cisplatin ( DDP) in reversing DDP resistance by PI3K/AKT/mTOR signaling pathway in nude mice bearing A 549/DDP tumor.METHODS:The patient-de-rived lung adenocarcinoma A 549/DDP cell xenograft model was established .The tumor-bearing nude mice were randomly divided into control group , Shenci capsule group , DDP group and Shenci capsule combined with DDP group .The mice in control group was treated with normal saline , while the mice in other groups were treated with different drugs for 21 d.After treatment, the mice were killed and lung cancer tissues were collected .Flow cytometry was used to analyze the cell cycle and apoptosis.FQ-PCR was used to determined the mRNA levels of PTEN , P-glycoprotein, PI3K, AKT and mTOR in A549/DDP lung tumor .RESULTS:Compared with control group , the cell proliferation in all the drug treatment groups was inhibited .Compared with other drug treatment groups , Shenci capsule combined with DDP blocked the cell cycle of A 549/DDP cells at G2/M phase, promoted the apoptosis rate , increased the mRNA expression of PTEN and inhibited the mRNA expression of P-glycoprotein, PI3K, AKT and mTOR.CONCLUSION:Shenci capsule increases the sensitivity of A 549/DDP resistant cells in nude mice to DDP by blocking PI 3K/AKT/mTOR signaling pathway , increasing the expression of PTEN or inhibiting P-glycoprotein-mediated resistance pathway .
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2017年第3期500-504,共5页 Chinese Journal of Pathophysiology
基金 广东省中医药局科研项目(No.20141176 No.20151279)
关键词 肺癌 参慈胶囊 顺铂耐药 PI3K/AKT/mTOR信号通路 PTEN P-糖蛋白 Lung cancer Shenci capsule DDP resistance PI3K/AKT/mTOR signaling pathway PTEN P-glycoprotein
  • 相关文献

参考文献9

二级参考文献292

  • 1马进元,于鹏,祝毓琳,朱步东.晚期或转移性非小细胞肺癌全身治疗进展[J].中国实用内科杂志,2013,33(S1):164-166. 被引量:18
  • 2韩婧,李江.DNA修复相关基因启动子甲基化和肿瘤化疗耐药的进展[J].上海交通大学学报(医学版),2011,31(1):95-98. 被引量:5
  • 3张超,杨娜,章雄文,丁健.靶向PI3K-Akt-mTOR信号通路抑制剂的研究进展[J].中国癌症杂志,2006,16(12):1064-1070. 被引量:22
  • 4Myers MP, Stolarov JP, Eng C, et al. PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase [J]. Proc Natl Acad Sci U S A, 1997,94(17) : 9052-9057.
  • 5Li J, Yen C, Liow D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [J]. Science, 1997, 275(5308): 1943-1947.
  • 6Dahia PL, Aguiar RC, Alberta J, et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via muhiple mechanisms in hematological malignancies [ J]. Hum Mol Genet, 1999, 8(2) : 185-193.
  • 7Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts [J]. Genes Dev, 1999, 13(22) : 2905-2927.
  • 8Shen YN, Zhang L, Gan Y, et al. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling [J]. J Biol Chem, 2006, 281 (12) : 7727-7736.
  • 9Wee KB, Aguda BD. Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death [ J]. Biophys J, 2006, 91 (4): 857-865.
  • 10Vasudevan KM, Gurvmunhy S, Rangnekar VM. Suppression of PTEN expression by NF-kappaB prevents apoptosis [ J]. Mol Cell Biol, 2004, 24(3): 1007-1021.

共引文献80

同被引文献168

引证文献22

二级引证文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部